Get notified when MBRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMoleculin presents positive cardiac safety data for lead cancer drug at ASCO conference
Filed May 29, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
medium
New clinical data presented at the 2026 ASCO Annual Meeting shows Annamycin, Moleculin's lead drug candidate, has a differentiated cardiac safety profile compared to similar cancer therapies.
Item 8.01: Press Release view on EDGAR → -
medium
The cardiac safety advantage addresses a key concern with anthracycline-class cancer drugs, which are known for potential heart toxicity, potentially improving Annamycin's competitive positioning.
Item 8.01: ASCO Data view on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Partner
Trade MBRX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · May 29, 2026 · How we verify